None listed
Conditions
Interventions
Tadalafil 20 mg Type of group
Tadalafil 20mg was given after having been treated with Sildenafil Citrate for at least ten (10) weeks.
Sponsors
ELI LILLY INTERAMERICA INC.,
Eligibility
Inclusion criteria
Inclusion criteria: 1) were male and at least 18 years of age; 2) have signed informed consent; 3) had a history of DE for at least 3 months; 4) were users of sildenafil at a stable dose for 6 weeks or more; 5) having anticipated having the same sexual partner during the study to record the answers to the efficacy questionnaires; 6) to have agreed not to use any other treatment for ED throughout the study except study medication.
Exclusion criteria
Exclusion criteria: Presenting impotence caused by other primary sexual disorders including premature ejaculation or impotence caused by an untreated endocrine disease. Have a history of radical prostatectomy Have a history of a penile implant. Having a clinically significant deformity in the penis in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:Disposition of the patient and his reason Measure:Patient choice of treatment (either sildenafil or tadalafil) for use in the extension phase Timepoints:14 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:PAIRS scale Measure:Assessment of sexual encounter attributes measured by the PAIRS scale including the Sexual Self-Confidence, Romance, and Time Pressure domains. Timepoints:26 weeks | — |
Countries
Austria, Brazil, Chile, Colombia, Costa Rica, Czech Republic, Israel, Malasya, Mexico, New Zealand, Peru, Philippines, Poland, Puerto Rico, Russian Federation, Singapore, Slovakia, Taiwan, Turkey, Venezuela
Outcome results
None listed